Docoh
Loading...

BCRX Biocryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug RAPIVAB was approved by FDA in Dec 2014. It has also been approved in Japan, Korea and China The company was founded in 1986 by Charles E. Bugg, Ph.D. and John A. Montgomery, Ph.D. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008 the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.

Company profile

Ticker
BCRX
Exchange
CEO
Jon Stonehouse
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
621413174

BCRX stock data

(
)

Calendar

1 Mar 21
13 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 272.13M 272.13M 272.13M 272.13M 272.13M 272.13M
Cash burn (monthly) (positive/no burn) (positive/no burn) 17.47M 14.56M 14.88M 11.43M
Cash used (since last report) n/a n/a 60.35M 50.32M 51.41M 39.51M
Cash remaining n/a n/a 211.77M 221.81M 220.72M 232.62M
Runway (months of cash) n/a n/a 12.1 15.2 14.8 20.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 Mar 21 Thackray Helen M. Common Stock Grant Aquire A No No 0 100,000 0 100,000
31 Mar 21 Thackray Helen M. Emp. Stock Option Common Stock Grant Aquire A No No 10.17 400,000 4.07M 400,000
18 Mar 21 Michael L Jones Common Stock Option exercise Aquire M No No 3.51 4,500 15.79K 5,348
18 Mar 21 Michael L Jones Emp. Stock Option Common Stock Option exercise Dispose M No No 3.51 4,500 15.79K 0
26 Feb 21 Steve Aselage Common Stock Grant Aquire A No No 10.78 927 9.99K 31,496
26 Feb 21 Theresa Heggie Common Stock Grant Aquire A No No 10.78 463 4.99K 13,849
26 Feb 21 Nancy J Hutson Common Stock Grant Aquire A No No 10.78 463 4.99K 64,756

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

68.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 177 153 +15.7%
Opened positions 40 27 +48.1%
Closed positions 16 37 -56.8%
Increased positions 57 60 -5.0%
Reduced positions 55 43 +27.9%
13F shares
Current Prev Q Change
Total value 1B 584.49M +71.1%
Total shares 120.72M 127.04M -5.0%
Total puts 1.15M 1.17M -2.2%
Total calls 1.26M 968.3K +29.8%
Total put/call ratio 0.9 1.2 -24.7%
Largest owners
Shares Value Change
BLK Blackrock 16.26M $121.13M +2.0%
Baker Bros. Advisors 12.7M $94.58M 0.0%
Vanguard 11.6M $86.42M +1.0%
STT State Street 11.06M $82.37M -31.7%
Sarissa Capital Management 8.18M $60.9M +68.2%
Citadel Advisors 6.5M $48.39M -25.0%
Deerfield Management 5.84M $43.48M +30.9%
Point72 Asset Management 3.23M $24.07M +410.7%
Oracle Investment Management 2.98M $22.21M +18.0%
Marshall Wace North America 2.8M $20.85M +89.0%
Largest transactions
Shares Bought/sold Change
STT State Street 11.06M -5.13M -31.7%
Sarissa Capital Management 8.18M +3.31M +68.2%
Millennium Management 286.63K -3.11M -91.6%
Point72 Asset Management 3.23M +2.6M +410.7%
Citadel Advisors 6.5M -2.17M -25.0%
Adage Capital Partners GP, L.L.C. 1.6M +1.6M NEW
Deerfield Management 5.84M +1.38M +30.9%
Marshall Wace North America 2.8M +1.32M +89.0%
Renaissance Technologies 1.28M +1.28M NEW
GS Goldman Sachs 303.64K -1.17M -79.3%
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: abide, absorption, adolescent, Anthony, appealing, AstraZeneca, Athyrium, attainment, behavior, biodefense, California, capped, capsule, carryforward, Cautionary, Chancery, column, contemporaneously, corroborated, covenant, cultural, culture, cybersecurity, dehydrogenase, Delinquent, discourage, doctrine, Doyle, drawn, duty, economy, EMPOWER, empty, enjoy, extinguishment, fat, fiduciary, fill, forum, France, friendly, Gayer, Germany, guarantor, hemoglobin, home, impute, imputed, inclusive, inconvenient, indefinite, Inline, inquiry, intake, Intermediate, Ireland, Isu, judicial, lactate, LDH, leaseback, Liechtenstein, linear, map, meal, monotherapy, NaN, nephrology, nonrenewal, obligor, opt, orladeyo, OrphanPacific, Overview, pattern, payoff, pharmacy, philosophy, PIK, prepaid, prepay, prescribing, purpose, pursuit, recalculated, recession, remote, reward, rewarding, risky, RPA, RPI, Scheme, shortly, situation, sized, smaller, spread, startup, stomach, truthful, unamortized, unnecessarily, unrecoverable, upcoming, voluntary, war, wellbeing, withdrew, workplace, writing
Removed: accept, adaptive, alanine, alleviate, amending, aminotransferase, Asia, attached, attributable, Australasia, bargaining, baseline, biopharmaceutical, blinded, Canadian, Carbohydrate, caution, ceasing, Chairman, circumstance, clarified, closed, cold, collectability, collective, combination, consecutive, constitute, convey, counterparty, diarrhea, dissolve, doubt, effectuate, enactment, endpoint, entirety, exceeded, exceeding, exploratory, Ferrier, Fifty, floating, forecast, formed, fulfilling, fulfillment, gastrointestinal, half, headache, Idera, impacting, infection, inhibition, insolvency, intramuscular, leased, licensee, liquid, liquidate, liquidating, Lynne, mark, marked, materialize, MDCP, MINE, modify, moved, onset, percentage, permanently, posting, Powell, presidential, prevail, prioritized, procure, progressive, projecting, promptly, prospect, qualitative, quantitative, recovered, recur, redeemable, redeemed, redemption, remeasurement, renew, repeal, represented, restating, retention, revaluation, revalue, revise, Sakigake, season, seasonality, sequence, shareholder, spot, stoppage, studying, substitution, suffering, superior, SUPPLEMENTARY, TCJA, transient, ulodesine, unanticipated, unchanged, unfold, Unregistered, UNRESOLVED, vaccine, VAS, visual, VUW, week, Wellington, wholly, worth